http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2758950-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2546c3f3c2cf69e68544b45e52eac3b |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 |
filingDate | 2020-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efc4e9d611ba0793031fdf90b754328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_517bb1a9a5d676db4823b3a15ae497f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d21ee6b4cc29775a57da810304c50807 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c42214ac73fa8f25e47bd3bdb812e6a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5e02a3d1e23fce133d0feb67bb1135b |
publicationDate | 2021-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2758950-C1 |
titleOfInvention | Method for diagnosing hepatic pathologies in dogs using cfa-mirnas |
abstract | FIELD: biotechnology.SUBSTANCE: invention relates to the field of veterinary science and biotechnology. Proposed is a method for using circulating caninefamiliaris (cfa) microRNAs (miRNAs) produced from hepatocytes as new non-invasive diagnostic biomarkers for accurately reflecting the type of ongoing hepatic pathologies in dogs with different morphologies of extrahepatic and intrahepatic congenital portosystemic shunts (ICPS). The method is implemented by extracting the total RNA from serum samples of dogs with the confirmed presence of ICPS and various hepatic pathologies, followed by reverse transcription with subsequent amplification in RT-PCR in real time using canine-specific primers for cfa-miR-122-5p, cfa-miR-34a-5p, cfa-miR-21-5p and cfa-miR-126-5p. All analyses were applied in three repeats for each sample, and the resulting average cycle threshold (Ct) for each tested microRNA was normalised relative to the average Ct of cfa-miRNA-16 (stably expressed endogenous control) and cel-miRNA-39 (exogenous spike in the control). The relative multiple change in each tested cfa-miRNA in the groups of ICPS compared to the corresponding healthy controls was then determined using the 2-ΔΔCtmethod. Tests have proved that cfa-miR-122 at a threshold value of ≥1.32 to 1.45 constitutes a diagnostic tool for microvesicular steatosis. Cfa-miR-34a at a threshold value of ≥ 1.15 to 1.23 constitutes a diagnostic tool for vacuolated hepatocytes with macrovesicular steatosis, as well as lipid or pigmented granuloma. Cfa-miR-21 at a threshold value of ≥ 1.07 to 1.23 constitutes a diagnostic tool for portal and parenchymal fibrosis. Cfa-miR-126 at a threshold value of ≥ 1.14 to 1.16 constitues a diagnostic tool for changing the hepatic blood supply in the form of arteriole proliferation and duct proliferation associated therewith in dogs with ICPS.EFFECT: invention provides a possibility of using the selected serum cfa-miRNAs as new non-invasive biomarkers for reflecting the histopathological and molecular events occurring in the liver in each type of shunt with high degree of sensitivity and specificity.1 cl, 1 tbl |
priorityDate | 2020-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1059.